Prospective study of chemoradiotherapy with gemcitabine and S-1 for borderline resectable or unresectable pancreatic cancer
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000011453
- Lead Sponsor
- Multicenter Clinical Study Group of Osaka
- Brief Summary
unpublished
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 50
Not provided
(1) Resectable pancreatic cancer (2) Presence or past history of Interstitial pneumonia or pulmonary fibrosis or possible (3) Watery diarrhea (4) Active infections (excluding viral hepatitis) (5) Severe cardiac disorder, renal disorder, liver disorder, ulcer with bleeding, intestinal tract paralysis, uncontrollable diabetes mellitus (6) Presence of pleural effusion or ascites requiring drainage (7) Presence of metastasis in central nervous system (8) Active double cancer except carcinoma in situ or intramucosal cancer (synchronous double cancer or asynchronous double cancer with disease-free duration to be within 3 years) (9) Treatment with phenytoin, potassium warfarin or flucytosine (10) Pregnant females or nursing mothers who can not stop lactation. Patients or partners, who don't attempt to doing contraception during the study period. (11) Severe mental disorder (12) Severe drug hypersensitivity (13) As determined by the principal investigator or the sub-investigator the subject is not adequate to participate in the trial
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method